IRIS
IZZO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.249
EU - Europa 1.231
SA - Sud America 608
AS - Asia 139
AF - Africa 16
OC - Oceania 2
Totale 3.245
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.074
IT - Italia 766
BR - Brasile 423
MX - Messico 139
UA - Ucraina 134
CN - Cina 107
NL - Olanda 94
CO - Colombia 53
DE - Germania 50
FI - Finlandia 44
EC - Ecuador 41
IE - Irlanda 37
ES - Italia 25
PE - Perù 25
AR - Argentina 22
CA - Canada 22
BO - Bolivia 21
FR - Francia 21
GB - Regno Unito 21
CI - Costa d'Avorio 16
CL - Cile 15
SE - Svezia 13
VN - Vietnam 12
CH - Svizzera 9
IN - India 8
VE - Venezuela 6
PT - Portogallo 5
CR - Costa Rica 4
HN - Honduras 4
SG - Singapore 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
IR - Iran 3
RO - Romania 3
AU - Australia 2
JP - Giappone 2
UY - Uruguay 2
BE - Belgio 1
DK - Danimarca 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
KR - Corea 1
PA - Panama 1
PK - Pakistan 1
RU - Federazione Russa 1
SV - El Salvador 1
VA - Santa Sede (Città del Vaticano) 1
Totale 3.245
Salva come PNG Salva come JPEG
Città #
Chandler 176
Amsterdam 93
Napoli 81
Jacksonville 67
Ashburn 61
Naples 60
Millbury 53
Princeton 44
Beijing 37
Rome 33
Boston 32
Nanjing 28
Milan 27
Des Moines 24
Lima 22
Quito 22
Mexico 21
São Paulo 21
Woodbridge 20
Medellín 18
Ottawa 18
Wilmington 17
La Paz 16
Dong Ket 12
Santiago 12
Bari 11
Bogotá 11
Falls Church 11
Lawrence 11
Shenyang 11
Cuenca 10
Salerno 10
Brasília 9
Caserta 9
Fortaleza 9
Salvador 9
Hebei 8
Nanchang 8
Seattle 8
Genova 7
Tijuana 7
Buenos Aires 6
Kronberg 6
Monterrey 6
Palmi 6
Veracruz 6
Belo Horizonte 5
Brescia 5
Florence 5
Houston 5
Mendoza 5
Redwood City 5
Rio De Janeiro 5
Santa Cruz 5
Verona 5
Campo Grande 4
Federal 4
Feira De Santana 4
Guadalajara 4
Göttingen 4
Illac 4
Jiaxing 4
Madrid 4
Mantova 4
Menlo Park 4
Messina 4
Saint-cyprien 4
São Luís 4
Bauru 3
Bologna 3
Bordeaux 3
Brindisi 3
Caracas 3
Castel San Giorgio 3
Cuauhtémoc 3
Dublin 3
Guarujá 3
Guayaquil 3
Hidalgo 3
Manaus 3
Morciano di Romagna 3
Mountain View 3
Natal 3
Palermo 3
Pisa 3
Pune 3
Reggio Nell'emilia 3
Santo Domingo 3
Siena 3
Sofia 3
Tegucigalpa 3
Tianjin 3
Turin 3
Washington 3
Zurich 3
Acerra 2
Alicante 2
Angri 2
Arequipa 2
Barcelona 2
Totale 1.382
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.325
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 268
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 80
Laboratory medicine: health evaluation in elite athletes 63
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 60
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 56
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 55
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 53
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 50
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 49
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 47
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 45
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 44
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 44
Spleen is the dark side of essential Thrombocitemia 43
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 43
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 42
SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods 41
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 40
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 39
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 39
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 38
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 38
Molecular Analysis of Cluster Headache 38
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 38
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 37
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 35
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 35
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 34
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 34
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 33
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 32
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 32
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 31
Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry 30
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 30
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 26
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 25
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 25
Molecular monitoring in chronic myeloid leukemia (CML) 25
Late appearance of t(8;14) with c-myc rearrangement and disappearance of JH rearrangement leading to aggressive progression in a case of low grade non Hodgkin’s lymphoma” 24
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale 24
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 24
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 23
Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe 23
MiR‐27a downregulates 14‐3‐3θ, RUNX1, AF4, and MLL‐AF4, crucial drivers of blast transformation in t(4;11) leukemia cells 20
Droplet digital pcr for bcr–abl1 monitoring in diagnostic routine: Ready to start? 19
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 18
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study 17
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. 14
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study 14
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 14
Wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes 14
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 12
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition 11
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 11
Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia 10
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype 8
Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical bcr-abl1 transcripts 7
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy 5
Totale 3.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.920
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201917 0 0 0 0 0 0 0 0 0 2 12 3
2019/2020239 77 6 16 6 14 21 2 9 3 8 42 35
2020/2021261 14 23 23 30 31 35 25 4 24 16 19 17
2021/2022452 33 4 6 6 6 17 21 18 51 28 143 119
2022/2023500 59 29 19 17 57 53 3 58 72 92 32 9
2023/2024299 17 51 71 17 22 52 12 41 8 8 0 0
Totale 3.454